Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student
04:22pm, Monday, 25'th Aug 2025
SEATTLE--(BUSINESS WIRE)--A coalition of American Jewish organizations have filed an amicus brief in the United States Court of Appeals for the Second Circuit in support of a Vermont federal court's c
In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump
06:20pm, Thursday, 21'st Aug 2025
People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.
Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
01:21pm, Tuesday, 05'th Aug 2025
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
10:56am, Tuesday, 05'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionabl
Amicus (FOLD) Q2 Revenue Jumps 22%
06:01pm, Friday, 01'st Aug 2025
Amicus (FOLD) Q2 Revenue Jumps 22%
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
04:04pm, Friday, 01'st Aug 2025
Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA, targeting $1 billion in revenue by 2028. The DMX-200 licensing deal opens a major market opportun
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
12:51pm, Friday, 01'st Aug 2025
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
09:16am, Thursday, 31'st Jul 2025
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.06 per share a year ago.
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
07:00am, Thursday, 31'st Jul 2025
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance inclu
In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data
06:20pm, Monday, 28'th Jul 2025
American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commission American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commiss
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
11:07am, Thursday, 24'th Jul 2025
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
07:00am, Monday, 21'st Jul 2025
PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at
PHILADELPHIA , July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus") on behalf of the company's shareholders. Year to d
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
07:00am, Wednesday, 25'th Jun 2025
PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (
